This activity has expired. Credit is no longer available.
This activity is supported by unrestricted educational grants from AstraZeneca; Bayer HealthCare Pharmaceuticals Inc.; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Novartis Pharmaceutical Corporation; and Taiho Oncology, Inc.

The Role of the Advanced Practitioner in Maintaining Adherence in Patients on Oral Oncolytics

Almost 40% of the total cost of targeted therapies in the US are now for oral formulations, up from 26% in 2010. This increase calls for APs to act as practice-to-patient liaison with limited resources.  This education will focus on how APs can overcome a variety of barriers for patient nonadherence to oral therapies and encourage patients to continue their regimens. 

Please visit the Oral Oncolytics Adherence Knowledge Center at:


These activities, certified for CME/CE/CPE credit, are jointly provided by

Annenberg Logo Harborside Press Logo
Copyright © 2010-2019 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.